EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Type 1 inhibitor of plasminogen activators distinction between latent activated and reactive center cleaved forms with thermal stability and monoclonal antibodies



Type 1 inhibitor of plasminogen activators distinction between latent activated and reactive center cleaved forms with thermal stability and monoclonal antibodies



Febs Letters 295(1-3): 102-106



Type-1 inhibitor of plasminogen activators (PAI-1) occurs in purified preparations in a latent form that can be activated with denaturants; in vivo, latency is prevented by binding to vitronectin. We have compared latent, denaturant-activated and reactive centre-cleaved human PAI-1 with respect to thermal stability and affinity to monoclonal antibodies. By both criteria, latent and cleaved PAI-1 are very similar or indistinguishable, and clearly different from active PAI-1. Our findings suggest tht the conformations of latent and reactive centre-cleaved PAI-1 are similar and resemble the so-called relaxed (R) serpin conformation, while that of active PAI-1 is different resembles the stressed (S) serpin conformation.

(PDF emailed within 1 workday: $29.90)

Accession: 007976077

Download citation: RISBibTeXText

PMID: 1765139



Related references

A spectroscopic study of the structures of latent, active and reactive-center-cleaved type-1 plasminogen-activator inhibitor. European Journal Of Biochemistry. 240(3): 550-555, 1996

Type-1 plasminogen-activator inhibitor: Conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility. European Journal of Biochemistry 248(3): 775-785, 1997

Conformational studies of plasminogen activator inhibitor type 1 by fluorescence spectroscopy: Analysis of the reactive centre of inhibitory and substrate forms, and of their respective reactive-centre cleaved forms. European Journal of Biochemistry 267(12): 3729-3734, June, 2000

Sequence requirements in the reactive-center loop of plasminogen-activator inhibitor-1 for recognition of plasminogen activators. European Journal of Biochemistry 237(1): 180-187, 1996

Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate, and cleaved forms. Biochemistry 34(3): 1064-1069, 1995

Biochemical and biophysical studies of reactive center cleaved plasminogen activator inhibitor type 1. The distance between P-3 anmd P-1' determined by donor-donor fluorescence energy transfer. Journal of Biological Chemistry 271(35): 21231-21238, 1996

A peptide mimicking the C-terminal part of the reactive center loop induces the transition to the latent form of plasminogen activator inhibitor type-1. Febs Letters 586(6): 686-692, 2012

Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. Journal of Biological Chemistry 260(21): 11581-7, 1985

Detection of specific forms of plasminogen activator inhibitor type 1 by monoclonal antibodies. Fibrinolysis 5(2): 109-116, 1991

Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies. Molecular and Cellular Endocrinology 45(2-3): 137-147, 1986

Hormonal regulation of extracellular plasminogen activators and 54000 molecular weight plasminogen activator inhibitor in human neoplastic cell lines studied with monoclonal antibodies. Molecular & Cellular Endocrinology 45(2-3): 137-148, 1986